Obinutuzumab beta (Bejescin)

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Neuromyelitis optica spectrum disorder (Bejescin, obinutuzumab beta) (CN)

This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Latest reported trial: NCT05862233 · Phase 3 · met primary endpoint · grade pending

Also in development:Systemic Lupus Erythematosus · Phase 3 · investigational in the USFollicular Lymphoma · Phase 3 · investigational in the US

Also approved (1)
CN
  • Neuromyelitis optica spectrum disorder (Bejescin, obinutuzumab beta)
Product first approved 2026Outside this platform's coverageen.antaranews.com

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
Follicular Lymphoma
Primary Membranous Nephropathy
Systemic Lupus Erythematosus
Other / comorbidity
NCT05314010 · Beijing Mabworks Biotech Co., Ltd.
2022-08-18 – 2027-03 · Neuromyelitis Optica Spectrum Disorder
What this study did
Phase 2 (1)
Systemic Lupus Erythematosus
NCT05796206 · Beijing Mabworks Biotech Co., Ltd.
2023-05-26 – 2026-07-02 · Systemic Lupus Erythematosus
What this study did
Phase 1/2 (4)
Follicular Lymphoma
NCT04110301 · Beijing Mabworks Biotech Co., Ltd.
2019-11-28 – 2025-05 · Follicular Lymphoma and Marginal Zone Lymphoma
What this study did
Primary Membranous Nephropathy
NCT05398653 · Beijing Mabworks Biotech Co., Ltd.
2022-02-24 – 2025-04-18 · Primary Membranous Nephropathy
What this study did
Systemic Lupus Erythematosus
NCT07044115 · Beijing Mabworks Biotech Co., Ltd.
2021-11-26 – 2025-08 · Lupus Nephritis
What this study did
Other / comorbidity
NCT04304040 · Beijing InnoCare Pharma Tech Co., Ltd.
2020-07-28 – 2025-12-30 · B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
What this study did
Phase 1 (1)
Other / comorbidity
NCT04103905 · Beijing Mabworks Biotech Co., Ltd.
2017-02-10 – 2020-05-29 · CD20-positive B Cell Non-Hodgkin Lymphoma
What this study did

Competitive landscape

This mechanism is crowded: 15 other tracked programmes target it, 8 of them ahead of this one.

This drug's own stage for Follicular Lymphoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Obinutuzumab Beta (Bejescin): this drugPhase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
EpcoritamabApprovedMultispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide Analognot yet gradedNo reviewed efficacy summary in this indication
ObinutuzumabApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Ocrelizumab
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
Ocrevus Zunovo
Approved(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
Ofatumumab
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20Reliable signal
NCT02213263: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4)
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic Antibodynot yet gradedNo reviewed efficacy summary in this indication
Rituximab-Abbs (Truxima)
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
TafasitamabApprovedMonoclonal antibodyCD19Reliable signalNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
Zanubrutinib (Brukinsa)ApprovedSmall moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
ABP 692
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
Acellbia
Phase 3(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
BCD-281
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
CT-P53
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
HLX01 (Hanlikang)
Phase 3(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
OdronextamabPhase 3Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
SurovatamigPhase 3Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
Zugocabtagene GeleucelPhase 1/2Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Obinutuzumab beta (Bejescin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
Phase 3Systemic Lupus ErythematosusRecruiting
Est. primary completion 2028-12 · NCT07405970 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

4 June 2026Priority reviewNMPA marketing application for obinutuzumab beta (Bejescin) in primary membranous nephropathy under priority review (reported 2026-06-04)
CN, NMPA · Beijing Mabworks Biotech · Source ↗